McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271–287

CAS  Article  Google Scholar 

Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM (2010) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 21:1943–1951

CAS  Article  Google Scholar 

Sampalis JS, Adachi JD, Rampakakis E, Vaillancourt J, Karellis A, Kindundu C (2012) Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence. J Bone Miner Res 27:202–210

CAS  Article  Google Scholar 

McClung MR, Lewiecki EM, Cohen SB, Bolognese GC, Woodson AH et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821–831

CAS  Article  Google Scholar 

Kamimura M, Nakamura Y, Ikegami S, Uchiyama S, Kato H, Taguchi A (2017) Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients. Osteoporos Int 28:559–566

CAS  Article  Google Scholar 

Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG (2010) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 25:72–81

CAS  Article  Google Scholar 

Nakamura T, Matsumoto T, Sugimoto T, Hosoi T, Miki T et al (2014) Clinical trials express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab 99:2599–2607

CAS  Article  Google Scholar 

Lewiecki EM (2009) Denosumab in postmenopausal osteoporosis: what the clinician needs to know. Ther Adv Musculoskelet Dis 1:13–26

CAS  Article  Google Scholar 

Moen MD, Keam SJ (2011) Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging 28:63–82

CAS  Article  Google Scholar 

Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR et al (2011) Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 26:1829–1835

CAS  Article  Google Scholar 

Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE et al (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48:3082–3092

CAS  Article  Google Scholar 

McClung MR, Lewiecki EM, Geller ML, Bolognese MA, Peacock M, Weinstein RL, Ding B, Rockabrand E, Wagman RB, Miller PD (2013) Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int 24:227–235

CAS  Article  Google Scholar 

Jones AR, Sim IW (2020) Denosumab failure associated with escape from suppression of bone resorption (in Eng). Bone 131:115157

Article  Google Scholar 

Baim S, Wilson CR, Lewiecki EM, Luckey MM, Downs RW Jr, Lentle BC (2005) Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry. J Clin Densitom 8:371–378

Article  Google Scholar 

Soen S, Fukunaga M, Sugimoto T, Soen T, Fujiwara S et al (2013) Diagnostic criteria for primary osteoporosis: year 2012 revision. J Bone Miner Metab 31:247–257

Article  Google Scholar 

Lodder MC, Lems WF, Ader HJ, Marthinsen AE, van Coeverden SC, Lips P, Netelenbos JC, Dijkmans BA, Roos JC (2004) Reproducibility of bone mineral density measurement in daily practice. Ann Rheum Dis 63:285–289

CAS  Article  Google Scholar 

Kushida K, Shiraki M, Nakamura T, Kishimoto H, Morii H et al (2004) Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study. J Bone Miner Metab 22:462–468

CAS  Article  Google Scholar 

Soen S, Arai Y, Matsuda S, Emori K, Ikezaki T, Osawa M (2020) A 3-year postmarketing study on the safety and effectiveness of once-monthly risedronate in Japanese patients with osteoporosis. Osteoporos Sarcopenia 6:191–198

Article  Google Scholar 

Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Ohashi Y, Nakamura T, Matsumoto T (2012) Three years of treatment with minodronate in patients with postmenopausal osteoporosis. J Bone Miner Metab 30:439–446

CAS  Article  Google Scholar 

Suzuki T, Nakamura Y, Kato H (2018) Efficacy, safety, and compliance of ibandronate treatment for 3 years in postmenopausal Japanese women with primary osteoporosis. Osteoporos Sarcopenia 4:69–72

Article  Google Scholar 

Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA, Burnett-Bowie SA, Neer RM, Leder BZ (2013) Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 382:50–56

CAS  Article  Google Scholar 

Perazella MA, Markowitz GS (2008) Bisphosphonate nephrotoxicity (in Eng). Kidney Int 74:1385–1393

CAS  Article  Google Scholar 

Ayasreh N, Fernandez-Llama P, Lloret MJ, Da Silva I, Ballarín J, Bover J (2013) Recombinant PTH associated with hypercalcaemia and renal failure (in Eng). Clin Kidney J 6:93–95

Article  Google Scholar 

Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S, Borenstein J, Kendler DL (2012) Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23:317–326

CAS  Article  Google Scholar 

Tada M, Inui K, Sugioka Y, Mamoto K, Okano T, Koike T, Nakamura H (2016) Reducing glucocorticoid dosage improves serum osteocalcin in patients with rheumatoid arthritis-results from the TOMORROW study. Osteoporos Int 27:729–735

CAS  Article  Google Scholar 

Kuroki Y, Kaji H, Kawano S, Kanda F, Takai Y, Kajikawa M, Sugimoto T (2008) Short-term effects of glucocorticoid therapy on biochemical markers of bone metabolism in Japanese patients: a prospective study. J Bone Miner Metab 26:271–278

CAS  Article  Google Scholar 

Petranova T, Sheytanov I, Monov S, Nestorova R, Rashkov R (2014) Denosumab improves bone mineral density and microarchitecture and reduces bone pain in women with osteoporosis with and without glucocorticoid treatment. Biotechnol Biotechnol Equip 28:1127–1137

Article  Google Scholar 

Hirooka Y, Nozaki Y, Inoue A, Li J, Shiga T, Kishimoto K, Sugiyama M, Kinoshita K, Funauchi M, Matsumura I (2020) Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment. Bone Rep 13:100293

Article  Google Scholar 

Coin A, Sergi G, Benincà P, Lupoli L, Cinti G, Ferrara L, Benedetti G, Tomasi G, Pisent C, Enzi G (2000) Bone mineral density and body composition in underweight and normal elderly subjects. Osteoporos Int 11:1043–1050

CAS  Article  Google Scholar 

Kobayakawa T, Miyazaki A, Saito M, Suzuki T, Takahashi J, Nakamura Y (2021) Denosumab versus romosozumab for postmenopausal osteoporosis treatment. Sci Rep 11:11801

CAS  Article  Google Scholar 

Kobayashi M, Sawada K, Yoshimura A, Yamamoto M, Shimizu A, Shimura K, Komura N, Miyamoto M, Ishida K, Kimura T (2020) Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study. BMC Womens Health 20:48

CAS  Article  Google Scholar 

Suzuki T, Nakamura Y, Kamimura M, Kato H (2018) Denosumab significantly improves lumbar spine bone mineral density more in treatment-naïve than in long-term bisphosphonate-treated patients. Bone Rep 8:110–114

CAS  Article  Google Scholar 

Miller PD, Pannacciulli N, Malouf-Sierra J, Singer A, Czerwiński E, Bone HG, Wang C, Huang S, Chines A, Lems W, Brown JP (2020) Efficacy and safety of denosumab vs bisphosphonates in postmenopausal women previously treated with oral bisphosphonates. Osteoporos Int 31:181–191

CAS  Article  Google Scholar 

Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 390:1585–1594

CAS  Article  Google Scholar 

McClung MR (2016) Cancel the denosumab holiday. Osteoporos Int 27:1677–1682

CAS  Article  Google Scholar 

Takeuchi T, Tanaka Y, Ishiguro N, Yamanaka H, Yoneda T, Ohira T, Okubo N, Genant HK, van der Heijde D (2016) Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Ann Rheum Dis 75:983–990

CAS  Article  Google Scholar 

Ebina K, Hirao M, Hashimoto J, Hagihara K, Kashii M, Kitaguchi K, Matsuoka H, Iwahashi T, Chijimatsu R, Yoshikawa H (2018) Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis. J Bone Miner Metab 36:478–487

CAS  Article  Google Scholar 

Pisani P, Renna MD, Conversano F, Casciaro E, Di Paola M, Quarta E, Muratore M, Casciaro S (2016) Major osteoporotic fragility fractures: Risk factor updates and societal impact (in Eng). World J Orthop 7:171–181

Article  Google Scholar